Browsing by Author "Ünal, Ali"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
Publication Efficacy and safety of ibrutinib therapy in patients with chronic lymphocytic leukemia: Retrospective analysis of real-life data(Galenos Yayıncılık, 2021-08-16) Tombak, Anıl; Tanrıkulu, Funda Pepedil; Durusoy, Salih Sertaç; Dinçyürek, Hüseyin Derya; Kaya, Emin; Ümit, Elif Gülsüm; Yavaşoğlu, İrfan; Mehtap, Özgür; Deveci, Burak; Özcan, Mehmet Ali; Terzi, Hatice; Okay, Müfide; Sayınalp, Nilgün; Yılmaz, Mehmet; Okan, Vahap; Kızıklı, Alperen; Özcan, Ömer; Çetin, Güven; Demircioğlu, Sinan; Aydoğdu, İsmet; Saydam, Güray; Davulcu, Eren Arslan; İlhan, Gül; Uçar, Mehmet Ali; Özet, Gülsüm; Akpınar, Seval; Turgut, Burhan; Berber, İlhami; Kurtoğlu, Erdal; Sönmez, Mehmet; Batur, Derya Selim; Yıldırım, Rahşan; Özkocamaz, Vildan; Güneş, Ahmet Kürşad; Sahip, Birsen; Ertop, Şehmus; Akay, Olga Meltem; Baştürk, Abdulkadir; Doğu, Mehmet Hilmi; Akdeniz, Aydan; Ünal, Ali; Seyhanlı, Ahmet; Gürkan, Emel; Çekdemir, Demet; Ferhanoğlu, Burhan; Özkocamaz, Vildan; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; 0000-0003-0014-7398; DLC-4894-2022Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +/- standard deviation: 64.6 +/- 10.3 years, 66.9% males) who had received at least one dose of ibrutinib were included in this retrospective multicenter, noninterventional hospital-registry study conducted at 33 centers across Turkey. Data on patient demographics, baseline characteristics, laboratory findings, and leukemia-cell cytogenetics were retrieved. Treatment response, survival outcome including overall survival (OS) and progression-free survival (PFS), and safety data were analyzed. Results: Overall, 36.7% of patients were categorized as Eastern Cooperative Oncology Group (ECOG) class 2-3, while 44.9% were in Rai stage 4. Fluorescence in situ hybridization revealed the presence of del(17p) in 39.8% of the patients. Patients received a median of 2.0 (range: 0-7) lines of pre-ibrutinib therapy. Median duration of therapy was 8.8 months (range: 0.4-58.0 months). The 1-year PFS and OS rates were 82.2% and 84.6%, respectively, while median PFS time was 30.0 (standard error, 95% confidence interval: 5.1, 20.0-40.0) months and median OS time was 37.9 (3.2, 31.5-44.2) months. Treatment response (complete or partial response), PFS time, and OS time were better with 0-2 lines versus 3-7 lines of prior therapy (p<0.001, p=0.001, and p<0.001, respectively), with ECOG class 0-1 versus class 2-3 (p=0.006, p=0.011, and p=0.001, respectively), and with Rai stage 0-2 versus 3-4 (p=0.002, p=0.001, and p=0.002, respectively). No significant difference was noted in treatment response rates or survival outcome with respect to the presence of comorbidity, bulky disease, or del(17p). While 176 adverse events (AEs) were reported in 74 (54.4%) patients, 46 of those 176 AEs were grade 3-4, including pneumonia (n=12), neutropenia (n=11), anemia (n=5), thrombocytopenia (n=5), and fever (n=5). Conclusion: This real-life analysis confirms the favorable efficacy and safety profile of long-term ibrutinib treatment while emphasizing the potential adverse impacts of poorer ECOG performance status, heavy treatment prior to ibrutinib, and advanced Rai stage on patient compliance, treatment response, and survival outcomes.Item Hematological and cytogenetic efficiency of interferon alpha 2a plus low dose cytarabine in chronic myelogenous leukemia: An interim analysis of multicenter study(Amer Soc Hematology, 1997-11-15) İlhan, O.; Özcan, Mühit; Yalçın, Arzu; Koç, H.; Beksaç, Mehmet; Ünal, Ali; Gülbaş, Zafer; Gürman, Günhan; Dündar, Semra; Ündar, Levent; Payzin, Bahriye; Akan, H.; Tunalı, Ahmet; Uludağ Üniversitesi/Tıp Fakültesi/Hemotoloji Anabilim Dalı.Item Interferon alpha 2a and low dose cytarabine in chronic myeloid leukemia: Second interim analysis of multicenter study(Amer Soc Hematology, 1998-11-15) İlhan, O.; Özcan, Muhit; Yalçın, Arzu; Koç, H.; Beksaç, Mehmet; Ünal, Ali; Gürman, Günhan; Dündar, Semra; Ündar, Levent; Payzin, Bahriye; Akan, H.; Tunalı, Ahmet; Uludağ Üniversitesi/Tıp Fakültesi/Hemotoloji Anabilim Dalı.Publication Patterns of hydroxyurea prescription and use in routine clinical management of polycythemia vera: A multicenter chart review study(Galenos Yayincilik, 2020-01-01) Büyükaşık, Yahya; Turgut, Mehmet; Saydam, Güray; Yavuz, Selim; Ünal, Ali; Ar, Muhlis Cem; Ayyıldız, Orhan; Altuntaş, Fevzi; Okay, Mufide; Çiftçiler, Rafiye; Meletli, Özgür; Soyer, Nur; Mastanzade, Metban; Güven, Zeynep; Soysal, Teoman; Karakuş, Abdullah; Yiğenoğlu, Tuğce Nur; Uçar, Barış; Gökçen, Ece; Tuğlular, Tülin; Ali, Rıdvan; ALİ, RIDVAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.; GXD-8209-2022Objective: This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV).Materials and Methods: This retrospective chart review study included PV patients who had received hydroxyurea therapy for at least 2 months after PV diagnosis. Data were collected from 10 representative academic medical centers.Results: Of 657 patients, 50.9% were in the high-risk group (age 60 years and/or history of thromboembolic event). The median duration of hydroxyurea therapy was 43.40 months for all patients; 70.2% of the patients had ongoing hydroxyurea therapy at last followup. Hydroxyurea was discontinued in 22.4% of the patients; the most common reason was death (38.5%). The predicted time until hydroxyurea discontinuation was 187.8 months (standard error: +/- 21.7) for all patients. This duration was shorter in females (140.3 +/- 37.7 vs. 187.8 +/- 29.7) (p=0.08). This trend was also observed in surviving patients aged >= 50 years at hydroxyurea initiation (122.2 +/- 12.4 vs. 187.8 +/- 30.7, p=0.03). Among the patients who were still on hydroxyurea therapy, 40.3% had a hematocrit concentration of >= 45% at their last followup visit, and the rate of patients with at least one elevated blood cell count was 67.8%.Conclusion: Hydroxyurea prescription patterns and treatment aims are frequently not in accordance with the guideline recommendations. Its discontinuation rate is higher in females.